RxDoctor Payments Data

Thomas Labruzzo, DO

Internal Medicine · North Kansas City, MONPI 1851363725

Payments from drug & device makers

$453in general payments, 2019–2025

Across 28 payments — averaging $16.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$116
  • Pfizer$83
  • Astellas Pharma US Inc$59
  • Sanofi-aventis U.S. LLC$53
  • E.r. Squibb & Sons, L.L.C.$33
  • Organogenesis Inc.$19
  • plus $91 from 6 others

What the payments were for

  • Food & beverage$453100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$453 in reported general payments places this provider in the 60th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$111,352
Medicare patients
427
Services billed
2,059

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban118$120,564
OzempicSemaglutide103$112,962
JardianceEmpagliflozin74$110,971
JanuviaSitagliptin Phosphate59$67,949
TrulicityDulaglutide33$50,119
XareltoRivaroxaban23$32,158
MounjaroTirzepatide19$23,358
MyrbetriqMirabegron22$21,473
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$17,347
Lantus SolostarInsulin Glargine,hum.Rec.Anlog128$17,079
FarxigaDapagliflozin Propanediol17$12,542
ArexvyRsvpref3 Antigen/As01e/Pf43$11,992
Humalog Kwikpen U-100Insulin Lispro41$10,611
AbrysvoRsv Vacc, Pref A And Pref B/Pf34$10,000
Mirabegron ErMirabegron16$9,607

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$83$130,564152 claims
MerckJanuvia$16$67,94959 claims
GSKTrelegy Ellipta, Arexvy, Shingrix, Anoro Ellipta$18$43,957113 claims
Astellas Pharma US IncMyrbetriq$59$21,47322 claims
AstraZenecaFarxiga, Symbicort$13$15,61330 claims
AbbVieSynthroid$116$3,76665 claims
Sanofi-aventis U.S. LLCLantus$53$3,13113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in North Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →